Inactive Instrument

EQRx, Inc.

Equities

EQRX

US26886C1071

Biotechnology & Medical Research

EQRx, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022

February 23, 2023 at 05:38 pm IST

EQRx, Inc. reported earnings results for the fourth quarter and full year ended December 31, 2022. For the fourth quarter, the company reported net loss was USD 22.18 million compared to net income of USD 1.22 million a year ago. Basic loss per share from continuing operations was USD 0.05. Diluted loss per share from continuing operations was USD 0.05.
For the full year, net loss was USD 169.09 million compared to USD 100.01 million a year ago. Basic loss per share from continuing operations was USD 0.36 compared to USD 0.31 a year ago. Diluted loss per share from continuing operations was USD 0.36 compared to USD 0.31 a year ago.

Latest news about EQRx, Inc.

Revolution Medicines Closes Acquisition of EQRx in All-Stock Deal	09/11	MT
EQRx, Inc. Announces Board Resignations	09/11	CI
EQRx, Inc.(NasdaqGM:EQRX) dropped from NASDAQ Composite Index	09/11	CI
EQRx, Inc.(NasdaqGM:EQRX) dropped from S&P Global BMI Index	09/11	CI
EQRx, Inc.(NasdaqGM:EQRX) dropped from S&P Biotechnology Select Industry Index	09/11	CI
EQRx, Inc.(NasdaqGM:EQRX) dropped from S&P TMI Index	09/11	CI
Revolution Medicines, Inc. completed the acquisition of EQRx, Inc. from a group of shareholders.	09/11	CI
Revolution Medicines, EQRx Stockholders Approve Merger	08/11	MT
EQRx, Inc.(NasdaqGM:EQRX) dropped from NASDAQ Biotechnology Index	08/11	CI
EQRx, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	07/11	CI
EQRx, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	09/23/09	CI
Hansoh Pharmaceutical Terminates License Agreement With EQRx for Aumolertinib; Shares Slump 10%	07/23/07	MT
EQRx, Inc. Provides Written Notice to G1 Therapeutics of its Termination of the Exclusive License Agreement	04/23/04	CI
EQRx, Inc. Provides Written Notice to Hansoh Healthtech Co., Ltd. and Jiangsu Hansoh Pharmaceutical Group Company Ltd. of Its Termination of the Strategic Collaboration License Agreement	04/23/04	CI
Revolution Medicines Shares Rise After Accord to Acquire EQRx in All-Stock Deal	01/23/01	MT
Sector Update: Health Care Stocks Decline Premarket Tuesday	01/23/01	MT
Sector Update: Health Care	01/23/01	MT
Revolution Medicines Agrees to Acquire EQRx in All-Stock Deal	01/23/01	MT
Transcript : EQRx, Inc., Revolution Medicines, Inc. - M&A Call	01/23/01
Revolution Medicines Agrees to Acquire EQRx in All-Stock Deal	01/23/01	MT
Revolution Medicines, Inc. entered into a definitive agreement to acquire EQRx, Inc. from a group of shareholders for approximately $930 million.	01/23/01	CI
Goldman Sachs Lowers EQRx's Price Target to $3 From $5, Neutral Rating Kept	10/23/10	MT
CStone Pharmaceuticals to Regain Commercialization Rights to Cancer Treatments	09/23/09	MT
EQRx, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	09/23/09	CI
Transcript : EQRx, Inc., Q1 2023 Earnings Call, May 08, 2023	09/23/09

Chart EQRx, Inc.

Duration

Period

More charts

Company Profile

EQRx, Inc. is a pharmaceutical company. The Company is engaged in developing medicines for some of the prevalent disease areas, including cancer and immune-inflammatory conditions. The Company brands include EQRx and Remaking Medicine. The Company's pipeline is comprised of approximately 10 programs, including both small molecules and biologics, with five clinical-stage programs, and several disclosed and undisclosed preclinical and drug engineering programs. Its clinical programs include Aumolertinib (EQ143), Lerociclib (EQ132), and Sugemalimab (EQ165). Aumolertinib (EQ143) is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). Lerociclib (EQ132) is a novel and oral small molecule cyclin-dependent kinase (CDK) 4/6 inhibitor. Sugemalimab (EQ165, also known as CS1001) is an anti-programmed cell death-ligand 1 (PD-L1) monoclonal antibody.

Sector

Biotechnology & Medical Research

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
MODERNA, INC.	+41.79%	54.04B
IQVIA HOLDINGS INC.	-0.56%	41.92B
LONZA GROUP AG	+49.62%	41.96B
CELLTRION, INC.	-7.20%	28.35B
ICON PUBLIC LIMITED COMPANY	+12.59%	26.35B
ALNYLAM PHARMACEUTICALS, INC.	-21.51%	19B
BIO-TECHNE CORPORATION	+6.92%	13B
UNITED THERAPEUTICS CORPORATION	+24.91%	12.19B
MEDPACE HOLDINGS, INC.	+29.60%	12.28B

Other Biotechnology & Medical Research